Myriad Genetics Inc logo

Myriad Genetics Inc

HAM:MYD (USA)   Ordinary Shares
€ 17.30 (+0.58%) Apr 24
At Loss
P/B:
2.14
Market Cap:
€ 1.57B ($ 1.69B)
Enterprise V:
€ 1.59B ($ 1.70B)
Volume:
-
Avg Vol (2M):
-
Also Trade In:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Myriad Genetics Inc ( ) from 1995 to Apr 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Myriad Genetics stock (HAM:MYD) PE ratio as of Apr 25 2024 is 0. More Details

Myriad Genetics Inc (HAM:MYD) PE Ratio (TTM) Chart

To

Myriad Genetics Inc (HAM:MYD) PE Ratio (TTM) Historical Data

Total 1221
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Myriad Genetics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss
2024-04-04 At Loss 2024-01-30 At Loss
2024-04-03 At Loss 2024-01-29 At Loss
2024-04-02 At Loss 2024-01-26 At Loss
2024-03-28 At Loss 2024-01-25 At Loss
2024-03-27 At Loss 2024-01-24 At Loss
2024-03-26 At Loss 2024-01-23 At Loss
2024-03-25 At Loss 2024-01-22 At Loss
2024-03-22 At Loss 2024-01-19 At Loss
2024-03-21 At Loss 2024-01-18 At Loss
2024-03-20 At Loss 2024-01-17 At Loss
2024-03-19 At Loss 2024-01-16 At Loss
2024-03-18 At Loss 2024-01-12 At Loss
2024-03-15 At Loss 2024-01-11 At Loss
2024-03-14 At Loss 2024-01-10 At Loss
2024-03-13 At Loss 2024-01-09 At Loss
2024-03-12 At Loss 2024-01-08 At Loss
2024-03-11 At Loss 2024-01-05 At Loss
2024-03-08 At Loss 2024-01-04 At Loss
2024-03-07 At Loss 2024-01-03 At Loss
2024-03-06 At Loss 2024-01-02 At Loss
2024-03-05 At Loss 2023-12-29 At Loss
2024-03-04 At Loss 2023-12-28 At Loss
2024-03-01 At Loss 2023-12-27 At Loss
2024-02-29 At Loss 2023-12-22 At Loss
2024-02-28 At Loss 2023-12-21 At Loss
2024-02-27 At Loss 2023-12-20 At Loss
2024-02-26 At Loss 2023-12-19 At Loss
2024-02-23 At Loss 2023-12-18 At Loss
2024-02-22 At Loss 2023-12-15 At Loss
2024-02-21 At Loss 2023-12-14 At Loss

Myriad Genetics Inc (HAM:MYD) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Myriad Genetics Inc logo
Myriad Genetics Inc
NAICS : 325413 SIC : 2835
ISIN : US62855J1043

Share Class Description:

HAM:MYD: Ordinary Shares
Description
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.